Ads
related to: atopic dermatitis- FAQs
Find Answers To Your Questions
& Understand Treatment Now
- Treatment Support
Discover Educational Resources
& Get Financial Support Information
- Home
Official Patient Website—
Get Treatment Info Today.
- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Sign Up
Register Or Activate Your Card—
Find Out If You're Eligible Today.
- Support Resources
Sign Up And Learn More About The
Patient Education Program Today.
- FAQs
Search results
...-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment...
KOIN News 6 Portland· 10 hours agoKeymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a...
The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now
InvestorPlace· 3 days agoOne of the best ways to spot opportunities in penny stocks to buy is by following insiders. After...
Tapinarof Cream Effective For AD, Down to Age 2 Years
Medscape· 5 days agoResults from two phase 3 trials showed that topical tapinarof, once a day, was effective and safe in patients with atopic dermatitis as young as 2 years old.
Goodbye inhalers? Chinese trial offers potential one-shot asthma cure
Interesting Engineering· 4 hours ago“The new cell therapy represents an option for asthma patients to achieve long-term remission of...
J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal
FierceBiotech· 6 days agoNot satisfied with just one new immunology deal this month, Johnson & Johnson is plunking down $1.25...
Rapid Rx Quiz: New Agents for Treating Atopic Dermatitis
Medscape· 5 days agoTopical corticosteroids were the initial treatment option for atopic dermatitis (AD) beginning in...
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
Zacks via Yahoo Finance· 5 days agoJ&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's...
...Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for...
Morningstar· 6 days agoYJT comprises all assets relating to NM26, an investigational first-in-class bi-specific antibody for the treatment of atopic dermatitis (AD) set to advance ...
Study finds 1.5 percent ruxolitinib cream safe, effective for teens with eczema
Medical Xpress· 2 days agoLong-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days ago- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si ...
Ads
related to: atopic dermatitis